Advancements in Human Microbiome Research - & It's Impact on Global Industry Revenue

Overview of This Study:

In order to estimate the current size of the human microbiome market, this study involved four major activities. A thorough investigation was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions, hypotheses, and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to estimate the overall market size. Subsequently, methods for data triangulation and market breakdown were employed to estimate the market size of various segments.

Market Size Estimation:

The entire market size for human microbiomes was estimated and validated using both top-down and bottom-up methods. The size of different market subsegments was also extensively estimated using these techniques. The research methodology used to estimate the market size includes the following:

# A great deal of secondary research has been done to identify the major players in the market and industry.
# Primary and secondary research has been used to determine the revenues that leading players in the human microbiome market generate.
# Primary sources have been used to verify all percentage shares, splits, and breakdowns that have been calculated using secondary sources.

Projected Surge in Revenue Generation:

With a predicted revenue of $0.3 billion in 2023 and a projected compound annual growth rate (CAGR) of 36.1% from 2023 to 2029, the global human microbiome market is expected to reach $1.7 billion.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Major Growth Influencing Factors:

Technological developments and the growing acceptance of personalized medicine are two major factors propelling the market's expansion. But the lack of knowledge about microbial interactions and regulatory obstacles may prevent the market from expanding.

Geographical Growth Dynamics:

The market for human microbiomes in 2023 was dominated by North America.

The market is divided into four geographic segments: North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to maintain its dominance of the market well into the forecast period, having done so in 2023. The North American market is expanding due to factors such as a well-established research infrastructure, technological advancements, the growing demand for precision medicine, a supportive regulatory environment, a robust biotechnology and healthcare industry, and easy access to funding and investment. The high cost of some human microbiomes, however, is impeding the market's growth and may prevent some customers—particularly smaller research institutions or clinics with tighter budgets—from adopting these products.

Global Leading Companies Operating in This Industry:

The market for human microbiome is highly consolidated, with key players strategizing to capture the market. Prominent players in the human microbiome market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc.  (US),  YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics Sciences (Switzerland).

Recent Developments:

# In November 2021, Seres Therapeutics collaborated with Bacthera to manufacture SER-109. The company is a leading manufacturer for recurrent Clostridioides difficile infection (rCDI). As per the agreement, Bacthera is establishing a dedicated facility for commercial manufacturing in its new Microbiome Center of Excellence, a manufacturing site dedicated to the production of LBPs located on Lonza’s Ibex campus in Visp, Switzerland.

# In June 2020, Enterome announced a new financing totaling $52.6million to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy.

# In July 2020, OptiBiotix Health PLC launched WellBiome, a revolutionary ingredient to support digestive, cardiovascular, and metabolic health.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Key Stakeholders:

# Manufacturers and distributors of human microbiome products
# Pharmaceutical and biotechnology companies
# Market research and consulting firms
# R&D centers
# Researchers and scientists
# Academic & research institutes